The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. / Jørgensen, Nils B; Dirksen, Carsten; Bojsen-Møller, Kirstine N; Jacobsen, Siv H; Worm, Dorte; Hansen, Dorte L; Kristiansen, Viggo B; Naver, Lars; Madsbad, Sten; Holst, Jens Juul.

In: Diabetes, Vol. 62, No. 9, 06.05.2013, p. 3044-3052.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jørgensen, NB, Dirksen, C, Bojsen-Møller, KN, Jacobsen, SH, Worm, D, Hansen, DL, Kristiansen, VB, Naver, L, Madsbad, S & Holst, JJ 2013, 'The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes', Diabetes, vol. 62, no. 9, pp. 3044-3052. https://doi.org/10.2337/db13-0022

APA

Jørgensen, N. B., Dirksen, C., Bojsen-Møller, K. N., Jacobsen, S. H., Worm, D., Hansen, D. L., Kristiansen, V. B., Naver, L., Madsbad, S., & Holst, J. J. (2013). The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes, 62(9), 3044-3052. https://doi.org/10.2337/db13-0022

Vancouver

Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL et al. The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes. 2013 May 6;62(9):3044-3052. https://doi.org/10.2337/db13-0022

Author

Jørgensen, Nils B ; Dirksen, Carsten ; Bojsen-Møller, Kirstine N ; Jacobsen, Siv H ; Worm, Dorte ; Hansen, Dorte L ; Kristiansen, Viggo B ; Naver, Lars ; Madsbad, Sten ; Holst, Jens Juul. / The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. In: Diabetes. 2013 ; Vol. 62, No. 9. pp. 3044-3052.

Bibtex

@article{41460ed3204d4af4ab1e04ff9682e3da,
title = "The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes",
abstract = "β-cell function is improved in patients with type 2 diabetes in response to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery. This has been linked to an exaggerated glucagon-like peptide 1 (GLP-1) secretion, but causality has not been established. The aim of this study was to investigate the role of GLP-1 in improving β-cell function and glucose tolerance and in regulating glucagon release after RYGB, using the GLP-1 receptor (GLP-1R)-specific antagonist, Exendin(9-39) (Ex-9). Nine patients with type 2 diabetes, were examined before, 1 week and 3 months after surgery. Each visit consisted of two experimental days, allowing a meal test with infusion of saline or Ex-9 in random order. After RYGB, glucose tolerance improved, β-cell glucose sensitivity (β-GS) doubled, the GLP-1 response greatly increased and glucagon secretion was augmented. GLP-1R blockade did not affect β-cell function and meal-induced glucagon release before the operation, but did impair glucose tolerance. After RYGB, β-GS decreased to preoperative levels, glucagon secretion increased and glucose tolerance was impaired by Ex-9 infusion. Thus, the exaggerated effect of GLP-1 after RYGB is of major importance for the improvement in β-cell function, and the controlof glucagon release and glucose tolerance in patients with type 2 diabetes. ClinicalTrials.gov (NCT01579981).",
author = "J{\o}rgensen, {Nils B} and Carsten Dirksen and Bojsen-M{\o}ller, {Kirstine N} and Jacobsen, {Siv H} and Dorte Worm and Hansen, {Dorte L} and Kristiansen, {Viggo B} and Lars Naver and Sten Madsbad and Holst, {Jens Juul}",
year = "2013",
month = may,
day = "6",
doi = "10.2337/db13-0022",
language = "English",
volume = "62",
pages = "3044--3052",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association",
number = "9",

}

RIS

TY - JOUR

T1 - The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes

AU - Jørgensen, Nils B

AU - Dirksen, Carsten

AU - Bojsen-Møller, Kirstine N

AU - Jacobsen, Siv H

AU - Worm, Dorte

AU - Hansen, Dorte L

AU - Kristiansen, Viggo B

AU - Naver, Lars

AU - Madsbad, Sten

AU - Holst, Jens Juul

PY - 2013/5/6

Y1 - 2013/5/6

N2 - β-cell function is improved in patients with type 2 diabetes in response to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery. This has been linked to an exaggerated glucagon-like peptide 1 (GLP-1) secretion, but causality has not been established. The aim of this study was to investigate the role of GLP-1 in improving β-cell function and glucose tolerance and in regulating glucagon release after RYGB, using the GLP-1 receptor (GLP-1R)-specific antagonist, Exendin(9-39) (Ex-9). Nine patients with type 2 diabetes, were examined before, 1 week and 3 months after surgery. Each visit consisted of two experimental days, allowing a meal test with infusion of saline or Ex-9 in random order. After RYGB, glucose tolerance improved, β-cell glucose sensitivity (β-GS) doubled, the GLP-1 response greatly increased and glucagon secretion was augmented. GLP-1R blockade did not affect β-cell function and meal-induced glucagon release before the operation, but did impair glucose tolerance. After RYGB, β-GS decreased to preoperative levels, glucagon secretion increased and glucose tolerance was impaired by Ex-9 infusion. Thus, the exaggerated effect of GLP-1 after RYGB is of major importance for the improvement in β-cell function, and the controlof glucagon release and glucose tolerance in patients with type 2 diabetes. ClinicalTrials.gov (NCT01579981).

AB - β-cell function is improved in patients with type 2 diabetes in response to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery. This has been linked to an exaggerated glucagon-like peptide 1 (GLP-1) secretion, but causality has not been established. The aim of this study was to investigate the role of GLP-1 in improving β-cell function and glucose tolerance and in regulating glucagon release after RYGB, using the GLP-1 receptor (GLP-1R)-specific antagonist, Exendin(9-39) (Ex-9). Nine patients with type 2 diabetes, were examined before, 1 week and 3 months after surgery. Each visit consisted of two experimental days, allowing a meal test with infusion of saline or Ex-9 in random order. After RYGB, glucose tolerance improved, β-cell glucose sensitivity (β-GS) doubled, the GLP-1 response greatly increased and glucagon secretion was augmented. GLP-1R blockade did not affect β-cell function and meal-induced glucagon release before the operation, but did impair glucose tolerance. After RYGB, β-GS decreased to preoperative levels, glucagon secretion increased and glucose tolerance was impaired by Ex-9 infusion. Thus, the exaggerated effect of GLP-1 after RYGB is of major importance for the improvement in β-cell function, and the controlof glucagon release and glucose tolerance in patients with type 2 diabetes. ClinicalTrials.gov (NCT01579981).

U2 - 10.2337/db13-0022

DO - 10.2337/db13-0022

M3 - Journal article

C2 - 23649520

VL - 62

SP - 3044

EP - 3052

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -

ID: 45840173